All News
Obintuzumab in Lupus Nephritis
In a post hoc analysis of the phase 2 NOBILITY trial, researchers found that treatment with obinutuzumab—an antibody that targets a protein expressed on certain immune cells—was superior to placebo for preserving kidney function and preventing flares in patients with lupus nephritis, a kidney con
Read ArticleACR Convergence Preview (11.10.2023)
Dr. Jack Cush reviews this past week's news on RheumNow.com and suggests a learning plan for those wanting to consume the upcoming ACR Convergence 2023 meeting.
Read ArticleRheumatoid Synovium Characterized by Six Cell Type Phenotypes
Research work from the Accelerating Medicines Partnership (AMP: RA/SLE) Network, was published in Nature and more specifically characterizes RA synovium into several cell-type abundance phenotypes (CTAPs). Could CTAPs known disease features or more effective future therapies?
Read ArticleDr. John Cush RheumNow ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)